Antigen presenting cell/tumor cell fusion vaccines for cancer immunotherapy

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 7, 2013, Pages 1545-1548

  Browning, Michael J ^a,b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Antigen presenting cell; Cancer; Fusion; Hybrid; Tumour; Vaccine

Indexed keywords

ANTIGEN PRESENTING CELL TUMOR CELL FUSION VACCINE; ANTINEOPLASTIC AGENT; CANCER VACCINE; DENDRITIC CELL TUMOR CELL FUSION VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLACEBO; UNCLASSIFIED DRUG;

BREAST TUMOR; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL MATURATION; CENTRAL NERVOUS SYSTEM TUMOR; COLON TUMOR; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EPSTEIN BARR VIRUS; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; KIDNEY TUMOR; LIVER TUMOR; LUNG TUMOR; LYMPHOBLASTOID CELL; MELANOMA; NERVOUS SYSTEM TUMOR; NONHUMAN; NOTE; SARCOMA; UTERINE CERVIX CARCINOMA;

ANTIGEN PRESENTING CELL; CANCER; FUSION; HYBRID; TUMOUR; VACCINE;

ANIMALS; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL FUSION; CELL- AND TISSUE-BASED THERAPY; HUMANS; HYBRID CELLS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS;

EID: 84880878540     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.24235     Document Type: Note

References (40)

1. Sims RB. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. Vaccine 2012; 30:4394-7; PMID:22122856; http://dx.doi.org/10.1016/j.vaccine.2011.11.058.
2. Guo Y, Wu M, Chen H, Wang X, Liu G, Li G, et al. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science1994; 263:518-20; PMID:7507262; http://dx.doi.org/10.1126/science.7507262.
3. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-8; PMID:12407406; http://dx.doi.org/10.1038/ni1102-991.
4. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997; 3:558-61; PMID:9142127; http://dx.doi.org/10.1038/nm0597-558.
5. Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic celltumor fusion vaccines. J Immunol 1998; 161:5516-24; PMID:9820528.
6. Gong J, Koido S, Chen D, Tanaka Y, Huang L, Avigan D, et al. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood 2002; 99:2512-7; PMID:11895787; http://dx.doi.org/10.1182/blood.V99.7.2512.
7. Chen D, Xia J, Tanaka Y, Chen H, Koido S, Wernet O, et al. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology 2003; 109:300-7; PMID:12757626; http://dx.doi.org/10.1046/j.1365-2567.2003.01656.x.
8. Siders WM, Vergilis KL, Johnson C, Shields J, Kaplan JM. Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Mol Ther 2003; 7:498-505; PMID:12727113; http://dx.doi.org/10.1016/S1525-0016(03)00044-3.
9. Xia J, Tanaka Y, Koido S, Liu C, Mukherjee P, Gendler SJ, et al. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol 2003; 170:1980-6; PMID:12574367.
10. Iinuma T, Homma S, Noda T, Kufe D, Ohno T, Toda G. Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. J Clin Invest 2004; 113:1307-17; PMID:15124022.
11. Suzuki T, Fukuhara T, Tanaka M, Nakamura A, Akiyama K, Sakakibara T, et al. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Clin Cancer Res 2005; 11:58-66; PMID:15671528.
12. Tanaka Y, Koido S, Ohana M, Liu C, Gong J. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells. J Immunol 2005; 174:1274-80; PMID:15661883.
13. Savai R, Schermuly RT, Schneider M, Pullamsetti SS, Grimminger F, Seeger W, et al. Hybrid-primed lymphocytes and hybrid vaccination prevent tumor growth of lewis lung carcinoma in mice. J Immunother 2006; 29:175-87; PMID:16531818; http://dx.doi.org/10.1097/01.cji.0000197096.38476.fc.
14. Yasuda T, Kamigaki T, Kawasaki K, Nakamura T, Yamamoto M, Kanemitsu K, et al. Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma. Cancer Immunol Immunother 2007; 56:1025-36; PMID:17131118; http://dx.doi.org/10.1007/s00262-006-0252-5.
15. Takeda A, Homma S, Okamoto T, Kufe D, Ohno T. Immature dendritic cell/tumor cell fusions induce potent antitumour immunity. Eur J Clin Invest 2003; 33:897-904; PMID:14511362; http://dx.doi.org/10.1046/j.1365-2362.2003. 01194.x.
16. Gong J, Koido S, Kato Y, Tanaka Y, Chen D, Jonas A, et al. Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk Res 2004; 28:1303-12; PMID:15475072; http://dx.doi.org/10.1016/j.leukres.2004.03.018.
17. Raje N, Hideshima T, Davies FE, Chauhan D, Treon SP, Young G, et al. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol 2004; 125:343-52; PMID:15086415; http://dx.doi.org/10. 1111/j.1365-2141.2004.04929.x.
18. Klammer M, Waterfall M, Samuel K, Turner ML, Roddie PH. Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia. Br J Haematol 2005; 129:340-9; PMID:15842657; http://dx.doi.org/10.1111/j.1365-2141.2005.05477.x.
19. Imura K, Ueda Y, Hayashi T, Itoh T, Shimizu K, Tamai H, et al. Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic celltumor cell hybrids generated by a newly developed electrofusion technique. Int J Oncol 2006; 29:531-9; PMID:16865268.
20. Rosenblatt J, Wu Z, Vasir B, Zarwan C, Stone R, Mills H, et al. Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. J Immunother 2010; 33:155-66; PMID:20145548; http://dx.doi.org/10.1097/CJI.0b013e3181bed253.
21. Trefzer U, Weingart G, Chen Y, Herberth G, Adrian K, Winter H, et al. Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int J Cancer 2000; 85:618-26; PMID:10699939; http://dx.doi.org/10.1002/(SICI)1097-0215(20000301)85:5〈618:: AIDIJC4〉3.0.CO;2-Z.
22. Krause SW, Neumann C, Soruri A, Mayer S, Peters JH, Andreesen R. The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother 2002; 25:421-8; PMID:12218780; http://dx.doi.org/10.1097/00002371-200209000-00006.
23. Märten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 2003; 14:483-94; PMID:12691613; http://dx.doi.org/10. 1089/104303403321467243.
24. Barbuto JA, Ensina LF, Neves AR, Bergami-Santos P, Leite KR, Marques R, et al. Dendritic celltumor cell hybrid vaccination for metastatic cancer. Cancer Immunol Immunother 2004; 53:1111-8; PMID:15185011; http://dx.doi.org/10.1007/ s00262-004-0551-7.
25. Trefzer U, Herberth G, Wohlan K, Milling A, Thiemann M, Sherev T, et al. Vaccination with hybrids of tumor and dendritic cells induces tumorspecific T-cell and clinical responses in melanoma stage III and IV patients. Int J Cancer 2004; 110:730-40; PMID:15146563; http://dx.doi.org/10.1002/ijc.20191.
26. Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004; 10:4699-708; PMID:15269142; http://dx.doi.org/10.1158/1078-0432.CCR-04-0347.
27. Trefzer U, Herberth G, Wohlan K, Milling A, Thiemann M, Sharav T, et al. Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results. Vaccine 2005; 23:2367-73; PMID:15755630; http://dx.doi.org/10.1016/j.vaccine.2005.01.081.
28. Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 2007; 30:749-61; PMID:17893567; http://dx.doi.org/10. 1097/CJI.0b013e3180de4ce8.
29. Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 2011; 117:393-402; PMID:21030562; http://dx.doi.org/10.1182/blood-2010-04- 277137.
30. Moviglia GA. Development of tumor B-cell lymphocyte hybridoma (TBH) autovaccination. Results of a phase I-II clinical trial. Transfus Sci 1996; 17:643-9; PMID:10168565.
31. Kugler A, Seseke F, Thelen P, Kallerhoff M, Müller GA, Stuhler G, et al. Autologous and allogenic hybrid cell vaccine in patients with metastatic renal cell carcinoma. Br J Urol 1998; 82:487-93; PMID:9806175; http://dx.doi.org/10.1046/j.1464-410X.1998.00794.x.
32. Newton DA, Acierno PM, Metts MC, Baron PL, Brescia FJ, Gattoni-Celli S. Semiallogeneic cancer vaccines formulated with granulocyte-macrophage colony-stimulating factor for patients with metastatic gastrointestinal adenocarcinomas: a pilot phase I study. J Immunother 2001; 24:19-26; PMID:11211145; http://dx.doi.org/10.1097/00002371-200101000-00003.
33. Dunnion DJ, Cywinski AL, Tucker VC, Murray AK, Rickinson AB, Coulie P, et al. Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro. Immunology 1999; 98:541-50; PMID:10594686; http://dx.doi.org/10.1046/ j.1365-2567.1999.00912.x.
34. Mohamed YS, Dunnion D, Teobald I, Walewska R, Browning MJ. Long-lived fusions of human haematological tumour cells and B-lymphoblastoid cells induce tumour antigen-specific cytotoxic T-cell responses in vitro. Immunobiology 2012; 217:719-29; PMID:22305004; http://dx.doi.org/10.1016/j.imbio.2011.12.001.
35. Mohamed YS, Dunnion D, Teobald I, Walewska R, Browning MJ. In vitro evaluation of human hybrid cell lines generated by fusion of B-lymphoblastoid cells and ex vivo tumour cells as candidate vaccines for haematological malignancies. Vaccine 2012; 30:6578-87; PMID:22939910; http://dx.doi.org/10. 1016/j.vaccine.2012.08.032.
36. Edwards PA, Smith CM, Neville AM, O'Hare MJ. A human-hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line. Eur J Immunol 1982; 12:641-8; PMID:7140810; http://dx.doi.org/10.1002/eji. 1830120804.
37. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115:925-35; PMID:19880495; http://dx.doi.org/10.1182/blood-2009-08-239186.
38. Warren EH, Fujii N, Akatsuka Y, Chaney CN, Mito JK, Loeb KR, et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 2010; 115:3869-78; PMID:20071660; http://dx.doi.org/10.1182/blood-2009-10-248997.
39. Montagna D, Turin I, Schiavo R, Montini E, Zaffaroni N, Villa R, et al. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor. Cytotherapy 2012; 14:80-90; PMID:21942841; http://dx.doi.org/10.3109/14653249.2011.610303.
40. Savai R, Schermuly RT, Pullamsetti SS, Schneider M, Greschus S, Ghofrani HA, et al. A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells. Cancer Res 2007; 67:5443-53; PMID:17545626; http://dx.doi.org/10.1158/0008-5472.CAN-06-3677.